Malabre Richard C
SEC insider (Form 3/4/5 filer). CIK 0002007730. SVP, Chief Accounting Officer at Akebia Therapeutics, Inc. (AKBA). 8 reported Form 4/5 transactions since Sep 2024; latest on Feb 2, 2026. Located in CAMBRIDGE, MA.
Companies Malabre Richard C has filed insider reports for
- Akebia Therapeutics, Inc. (AKBA): Officer, SVP, Chief Accounting Officer
Malabre Richard C
CIK: 0002007730
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Akebia Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Feb 2, 2026AKBA
Akebia Therapeutics, Inc.
SaleDirect36.1K shares at avg. $1.39$50K - Feb 2, 2026AKBA
Akebia Therapeutics, Inc.
SaleDirect13.4K shares at avg. $1.39$19K - Jan 30, 2026AKBA
Akebia Therapeutics, Inc.
AwardDirect79K shares- - Jun 9, 2025AKBA
Akebia Therapeutics, Inc.
SaleDirect15K shares at avg. $4.01$60K - Jun 9, 2025AKBA
Akebia Therapeutics, Inc.
ExerciseDirect15K shares at avg. $1.68$25K - Jun 4, 2025AKBA
Akebia Therapeutics, Inc.
SaleDirect13.3K shares at avg. $3.53$47K - Feb 3, 2025AKBA
Akebia Therapeutics, Inc.
SaleDirect30.2K shares at avg. $2.10$63K - Jan 31, 2025AKBA
Akebia Therapeutics, Inc.
AwardDirect85K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | Sale | 36,142 | $1.39 | $50,237 | Direct |
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | Sale | 13,382 | $1.39 | $18,601 | Direct |
| Jan 30, 2026 | AKBA Akebia Therapeutics, Inc. | Award | 79,000 | - | $0 | Direct |
| Jun 9, 2025 | AKBA Akebia Therapeutics, Inc. | Sale | 15,000 | $4.01 | $60,150 | Direct |
| Jun 9, 2025 | AKBA Akebia Therapeutics, Inc. | Exercise | 15,000 | $1.68 | $25,200 | Direct |
| Jun 4, 2025 | AKBA Akebia Therapeutics, Inc. | Sale | 13,334 | $3.53 | $47,069 | Direct |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | Sale | 30,202 | $2.10 | $63,424 | Direct |
| Jan 31, 2025 | AKBA Akebia Therapeutics, Inc. | Award | 85,000 | - | - | Direct |
1-8 of 8 transactions